Drug Profile
Estrogen dementia therapeutics - MIGENIX/Wyeth
Latest Information Update: 13 Aug 2009
Price :
$50
*
At a glance
- Originator MIGENIX
- Developer Wyeth
- Class
- Mechanism of Action Estrogen receptor modulators; Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 21 Sep 2004 Micrologix Biotech is now called MIGENIX
- 06 Sep 2004 MitoKor has been acquired and merged into Micrologix Biotech
- 27 Jun 2001 Phase-III clinical trials in Alzheimer's disease in USA (unspecified route)